These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 38443329)

  • 101. Efficacy and safety of high-dose esomeprazole-amoxicillin dual therapy for Helicobacter pylori rescue treatment: a multicenter, prospective, randomized, controlled trial.
    Bi H; Chen X; Chen Y; Zhao X; Wang S; Wang J; Lyu T; Han S; Lin T; Li M; Yuan D; Liu J; Shi Y
    Chin Med J (Engl); 2022 Jul; 135(14):1707-1715. PubMed ID: 36193978
    [TBL] [Abstract][Full Text] [Related]  

  • 102. A "new" option in Helicobacter pylori eradication: High-dose amoxicillin dual therapy outperforms bismuth quadruple therapy in a high dual resistance setting.
    Macedo Silva V; Lima Capela T; Freitas M; Boal Carvalho P; Magalhães J; Cotter J
    Helicobacter; 2023 Jun; 28(3):e12962. PubMed ID: 36828647
    [TBL] [Abstract][Full Text] [Related]  

  • 103. P-CAB
    Jiang Y; Zhang R; Fang Y; Zhao R; Fu Y; Ren P; Zhan Q; Shao M
    Therap Adv Gastroenterol; 2024; 17():17562848241241223. PubMed ID: 38751605
    [TBL] [Abstract][Full Text] [Related]  

  • 104. The efficacy and safety of vonoprazan in quadruple therapy for
    Zhuang X; Jiang H; Jin D; Sun M; Wang Z; Wang X
    Gastroenterol Rep (Oxf); 2024; 12():goae036. PubMed ID: 38628396
    [TBL] [Abstract][Full Text] [Related]  

  • 105. Efficacy and safety of bismuth quadruple regimens containing minocycline and vonoprazan for eradication of
    He Q; Ou Y; Zhu H; Chen Z; Yang D; Cheng Q; Yin X; Xiao L; Cai L; Ye Y; Xu X; Liao J
    JGH Open; 2024 May; 8(5):e13070. PubMed ID: 38699469
    [TBL] [Abstract][Full Text] [Related]  

  • 106. Novel Information Regarding the Treatment of
    Kiani F; Khademolhosseini S; Mohammadi J; Tavasol A; Hajibeygi R; Fathi M; Dousti M
    Curr Rev Clin Exp Pharmacol; 2024; 19(2):184-203. PubMed ID: 36683319
    [TBL] [Abstract][Full Text] [Related]  

  • 107. The effect of supplementing with
    Chen Y; Teng T; Su Y; Chen WZ
    Front Med (Lausanne); 2024; 11():1344702. PubMed ID: 38695028
    [TBL] [Abstract][Full Text] [Related]  

  • 108. Role of probiotic as adjuvant in treating various infections: a systematic review and meta-analysis.
    Nelwan EJ; Herdiman A; Kalaij AGI; Lauditta RK; Yusuf SM; Suarthana E
    BMC Infect Dis; 2024 May; 24(1):505. PubMed ID: 38773400
    [TBL] [Abstract][Full Text] [Related]  

  • 109. Simplified
    Gao W; Liu J; Wang X; Li J; Zhang X; Ye H; Li J; Dong X; Liu B; Wang C; Xu Y; Teng G; Tian Y; Dong J; Ge C; Cheng H
    Gut; 2024 Jun; ():. PubMed ID: 38906695
    [TBL] [Abstract][Full Text] [Related]  

  • 110. Comparative Efficacy and Safety of Potassium-Competitive Acid Blockers vs. Proton Pump Inhibitors for Peptic Ulcer with or without
    Ouyang M; Zou S; Cheng Q; Shi X; Zhao Y; Sun M
    Pharmaceuticals (Basel); 2024 May; 17(6):. PubMed ID: 38931366
    [TBL] [Abstract][Full Text] [Related]  

  • 111. Novel therapeutic regimens against
    Huang TT; Cao YX; Cao L
    Front Microbiol; 2024; 15():1418129. PubMed ID: 38912349
    [No Abstract]   [Full Text] [Related]  

  • 112. Vonoprazan-based versus proton pump inhibitor-based therapy in
    Chen PY; Tsai FP; Chen MJ; Yang HY; Wu MS; Liou JM
    Gut; 2024 Apr; 73(5):872-874. PubMed ID: 37001979
    [No Abstract]   [Full Text] [Related]  

  • 113. Comparing Short-Term Dual vs Standard Quadruple Therapy for Helicobacter pylori Eradication.
    Lunagariya Y; Shah M; Lad S; Chauhan S; Rawat V; Bairwa Y; Tailor C; Borkar V; Chopra S; Sasikumar D; Ingle M
    Am J Gastroenterol; 2024 Jul; ():. PubMed ID: 39016395
    [No Abstract]   [Full Text] [Related]  

  • 114. Correction: Vonoprazan: A Review in Helicobacter pylori Infection.
    Shirley M
    Drugs; 2024 May; 84(5):621. PubMed ID: 38739332
    [No Abstract]   [Full Text] [Related]  

  • 115. Re-evaluating the Proposed Association Between Vonoprazan and Gastric Cancer Following Eradication of H. pylori Infection.
    Howden CW; Chey WD; Shah SC
    Clin Gastroenterol Hepatol; 2024 May; ():. PubMed ID: 38729385
    [No Abstract]   [Full Text] [Related]  

  • 116. Meta-analysis of Helicobacter pylori eradication therapy using vonoprazan as an acid suppressor compared with bismuth quadruple therapy.
    Yang H; Zhang M; Ma G; Yang J; Wang K; Jiang S; Dong J; Han Y
    Helicobacter; 2024; 29(2):e13059. PubMed ID: 38443329
    [TBL] [Abstract][Full Text] [Related]  

  • 117. Comparison of vonoprazan-based dual therapy with vonoprazan-based bismuth quadruple therapy for treatment-naive patients with Helicobacter pylori infection: A propensity score matching analysis.
    Liu Z; Chen X; Sun DJ; Zhao WW; Kou L; Zheng WW; Hao JR; Gao FY
    Medicine (Baltimore); 2024 Mar; 103(10):e37476. PubMed ID: 38457567
    [TBL] [Abstract][Full Text] [Related]  

  • 118. Review: A Japanese population-based meta-analysis of vonoprazan versus PPI for Helicobacter pylori eradication therapy: Is superiority an illusion?
    Dong SQ; Singh TP; Wei X; Yao H; Wang HL
    Helicobacter; 2017 Dec; 22(6):. PubMed ID: 28884937
    [TBL] [Abstract][Full Text] [Related]  

  • 119. Effectiveness and safety of vonoprazan-based regimen for Helicobacter pylori eradication: A meta-analysis of randomized clinical trials.
    Yang C; Li S; Huang T; Lin H; Jiang Z; He Y; Yuan J; An H
    J Clin Pharm Ther; 2022 Jul; 47(7):897-904. PubMed ID: 35247003
    [TBL] [Abstract][Full Text] [Related]  

  • 120.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.